Title: Assessing prognostic value of early tumor shrinkage and depth of response in first-line
therapy for patients with advanced unresectable pancreatic cancer
Version: 3 Date: 21 May 2021
Reviewer's report:
This manuscript demonstrated the impact of ETS and DpR on the outcome of unresectable
pancreatic cancer patients. I reviewed this manuscript with interest, and I think that the results
are clearly presented. However, I am concerned about some points as below. This paper could
be more informative if the following were addressed.
1. In Table 1, as for histology, 65 patients of enrolled 90 patients were classified as
“unclassified”. The author describes that the enrolled patients had histopathologically confirmed
RMPC in page 5. Among pancreatic cancer, unclassified cancer is not generally major, and
therefore, I think the part of “unclassified” in this report might be too much. The author must
show the reason.
2. In this report, 15 regimens were included, and number of almost them were very small.
Caterina V et al reported the effect of ETS and DpR on the outcome was dependent on the first-
line regimen, FOLFOXIRI or G+Nab-paclitaxel. Was there some difference among regimens in
this research? Please discuss the difference of the effect based on the regimen.
Title: Assessing prognostic value of early tumor shrinkage and depth of response in first-line
therapy for patients with advanced unresectable pancreatic cancer
Version: 3 Date: 21 May 2021
Reviewer's report:
This manuscript demonstrated the impact of ETS and DpR on the outcome of unresectable
pancreatic cancer patients. I reviewed this manuscript with interest, and I think that the results
are clearly presented. However, I am concerned about some points as below. This paper could
be more informative if the following were addressed.
1. In Table 1, as for histology, 65 patients of enrolled 90 patients were classified as
“unclassified”. The author describes that the enrolled patients had histopathologically confirmed
RMPC in page 5. Among pancreatic cancer, unclassified cancer is not generally major, and
therefore, I think the part of “unclassified” in this report might be too much. The author must
show the reason.
2. In this report, 15 regimens were included, and number of almost them were very small.
Caterina V et al reported the effect of ETS and DpR on the outcome was dependent on the first-
line regimen, FOLFOXIRI or G+Nab-paclitaxel. Was there some difference among regimens in
this research? Please discuss the difference of the effect based on the regimen.
Please review this paper.
user
Title: Assessing prognostic value of early tumor shrinkage and depth of response in first-line
therapy for patients with advanced unresectable pancreatic cancer
Version: 3 Date: 21 May 2021
Reviewer's report:
This manuscript demonstrated the impact of ETS and DpR on the outcome of unresectable
pancreatic cancer patients. I reviewed this manuscript with interest, and I think that the results
are clearly presented. However, I am concerned about some points as below. This paper could
be more informative if the following were addressed.
1. In Table 1, as for histology, 65 patients of enrolled 90 patients were classified as
“unclassified”. The author describes that the enrolled patients had histopathologically confirmed
RMPC in page 5. Among pancreatic cancer, unclassified cancer is not generally major, and
therefore, I think the part of “unclassified” in this report might be too much. The author must
show the reason.
2. In this report, 15 regimens were included, and number of almost them were very small.
Caterina V et al reported the effect of ETS and DpR on the outcome was dependent on the first-
line regimen, FOLFOXIRI or G+Nab-paclitaxel. Was there some difference among regimens in
this research? Please discuss the difference of the effect based on the regimen.
assistant